BRIEF published on 05/19/2026 at 07:05, 4 months 7 days ago Innate Pharma à la Conférence Jefferies Global Healthcare Immunothérapie Cancer Innate Pharma Conférence Jefferies Anticorps Thérapeutiques
BRIEF published on 05/19/2026 at 07:05, 4 months 7 days ago Innate Pharma participera à la conférence mondiale sur les soins de santé de Jefferies Biotechnologie Immunothérapie Traitement Du Cancer Innate Pharma Conférence Jefferies
BRIEF published on 05/19/2026 at 07:05, 4 months 7 days ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
PRESS RELEASE published on 05/19/2026 at 07:00, 4 months 7 days ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Jefferies Global Healthcare 2026 à New York. La société de biotechnologies développe des traitements d'immunothérapies contre le cancer Conference Cancer Innate Pharma Biotechnologies Immunothérapies
PRESS RELEASE published on 05/19/2026 at 07:00, 4 months 7 days ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
BRIEF published on 04/17/2026 at 21:05, 5 months 8 days ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 5 months 8 days ago Innate Pharma dévoile des résultats intermédiaires prometteurs dans l'étude de phase 2 MATISSE Essais Cliniques Cancer Du Poumon Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 5 months 8 days ago Innate Pharma présente des résultats intermédiaires de l'essai MATISSE au congrès AACR Cancer Du Poumon Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
BRIEF published on 04/17/2026 at 21:05, 5 months 8 days ago Innate Pharma presents interim results from the MATISSE trial at the AACR congress Lung Cancer Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
PRESS RELEASE published on 04/17/2026 at 21:00, 5 months 8 days ago Inside Information / Other news releases Innate Pharma to present interim results of IPH5201 in MATISSE Phase 2 study at AACR 2026. Study aims to enhance NSCLC treatment with anti-CD39 monoclonal antibody NSCLC Innate Pharma AACR 2026 MATISSE Phase 2 IPH5201
Published on 09/26/2026 at 01:00, 12 hours 54 minutes ago Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 12 hours 54 minutes ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 15 hours 39 minutes ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 20 hours 24 minutes ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 22 hours 54 minutes ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 07:45, 6 hours 9 minutes ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 13 hours 53 minutes ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 18:30, 19 hours 24 minutes ago 029 Group SE: Publication of Half-Year Report 2026
Published on 09/25/2026 at 18:00, 19 hours 54 minutes ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.08.26
Published on 09/25/2026 at 17:45, 20 hours 9 minutes ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 20 hours 14 minutes ago Availability of the 2026 half-year financial report
